Seelos Therapeutics Inc (NASDAQ:SEEL) major shareholder Raj Mehra bought 133,333 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $0.93 per share, for a total transaction of $123,999.69. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
SEEL stock opened at $0.93 on Friday. Seelos Therapeutics Inc has a twelve month low of $0.72 and a twelve month high of $7.49. The business’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.18. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.93 and a quick ratio of 2.93.
A number of equities research analysts recently weighed in on SEEL shares. Zacks Investment Research downgraded Seelos Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 21st. HC Wainwright lifted their target price on Seelos Therapeutics from $2.00 to $4.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Finally, Benchmark started coverage on Seelos Therapeutics in a research report on Thursday, November 14th. They set a “buy” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Seelos Therapeutics has an average rating of “Buy” and an average price target of $4.44.
A number of institutional investors and hedge funds have recently made changes to their positions in SEEL. Renaissance Technologies LLC grew its position in Seelos Therapeutics by 10.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,118,623 shares of the company’s stock worth $1,499,000 after acquiring an additional 108,665 shares during the last quarter. Sabby Management LLC bought a new stake in Seelos Therapeutics during the 3rd quarter worth approximately $451,000. Virtu Financial LLC bought a new stake in Seelos Therapeutics during the 3rd quarter worth approximately $68,000. Wedbush Securities Inc. grew its position in Seelos Therapeutics by 412.7% during the 3rd quarter. Wedbush Securities Inc. now owns 82,028 shares of the company’s stock worth $75,000 after acquiring an additional 66,028 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Seelos Therapeutics by 104.2% during the 2nd quarter. Vanguard Group Inc. now owns 239,222 shares of the company’s stock worth $524,000 after acquiring an additional 122,086 shares during the last quarter. Hedge funds and other institutional investors own 12.07% of the company’s stock.
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
See Also: How to Invest in an Index Fund
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.